Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab with Bevacizumab and Docetaxel in Advanced Non-Squamous NSCLC
NCT06182800Phase 2Not yet recruiting
- Sponsor
- Xinxiang Medical University First Affiliated Hospital
- Start
- Dec 2023
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Xinxiang Medical University First Affiliated Hospital. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT06182800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06182800.